All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the best strategies for long-term management of hematotoxicity associated with CAR-T?

During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub spoke to Marion Subklewe, LMU, Munich, DE. We asked, What are the best strategies for long-term management of hematotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy?  

What are the best strategies for long-term management of hematotoxicity associated with CAR-T?

 Subklewe begins by outlining findings on the high number of patients presenting with neutropenia and cytopenia post CAR-T. She goes on to identify three clinical phenotypes of neutropenia and their implications. Subklewe explains a scoring system predicting hematotoxicity, which can support risk stratification. She discusses prophylaxis regimens including aciclovir, cotrimoxazole, G-CSF immunoglobulin, and antifungals. Finally, she highlights the importance of monitoring patients after CAR-T.

 

Share:
More about...